LivaNova Director Sells 1,650 Shares for $131,500

Director Francesco Bianchi sold 1,650 ordinary shares of LivaNova(NASDAQ:LIVN) on Aug. 31, 2026, according to a recent SEC Form 4 filing.

Transaction summary

Metric	Value
Transaction value	$131,500
Shares sold (directly held)	1,650
Post-transaction shares (directly held)	7,934
Post-transaction value	$633,212

Transaction value based on SEC Form 4 weighted average sale price ($79.72); post-transaction value based on Aug. 31, 2026, market close ($79.81).

Key questions

• What was the scale of this transaction relative to the director's total equity position?
  The sale involved 1,650 shares, which represented 17% of the 9,584 shares held directly by the director prior to the Aug. 31, 2026, transaction date.
• How does the execution price compare to recent market valuation levels?
  The shares were sold at $79.72 per share, while the stock was priced at $80.16 as of the Sept. 1, 2026, market close.
• What core business segments currently define the company's clinical focus?
  The company develops therapeutic solutions through its Cardiopulmonary division, which provides oxygenators and heart-lung machines, and its Neuromodulation segment, which focuses on the VNS Therapy System.
• What is the broader context of insider ownership following this disposition?
  The director now holds a direct stake of 7,934 shares, contributing to a total insider ownership level of 0.01% for the company.

Company Overview

Metric	Value
Share Price (as of market close 2026-09-01)	$80.16
Market Capitalization	$4.3 billion
Revenue (TTM)	$1.5 billion
Net Income (TTM)	$188.6 million

Company Snapshot

• LivaNova develops and manufactures therapeutic medical devices across three primary segments: Cardiopulmonary products, including oxygenators and heart-lung machines for cardiac procedures, Neuromodulation devices, such as the VNS Therapy System for vagus nerve stimulation, and Advanced Therapies solutions, generating revenue through device sales and related services to healthcare institutions globally.
• The company operates a specialized medical device business model centered on developing proprietary therapeutic platforms that address unmet clinical needs, with revenue derived from direct sales to hospitals, surgical centers, and healthcare systems, complemented by recurring revenue from device maintenance, consumables, and clinical support services.
• LivaNova serves cardiac surgeons, neurosurgeons, and interventional specialists in acute care settings, targeting hospitals and surgical centers that perform cardiopulmonary procedures and treat patients with drug-resistant neurological conditions. Its global customer base spans North America, Europe, and international markets.

LivaNova is a specialized medical technology company with a $4.3 billion market capitalization, employing 3,300 professionals across global operations headquartered in Gloucester. The company has demonstrated strong financial performance with TTM revenue of $1.5 billion and net income of $188.6 million, reflecting robust demand for its therapeutic device platforms in cardiac and neuromodulation markets. LivaNova maintains a competitive position through proprietary device technologies, established clinical relationships with leading surgeons and specialists, and a diversified product portfolio addressing critical therapeutic needs in cardiopulmonary and neurological treatment.

What this transaction means for investors

On Aug. 31, Bianchi sold 1,650 directly held shares, creating a transaction valued at $131,500. While the sale reduced the insider's total holdings, this doesn't appear to be a transaction that shareholders should be overly concerned with. Over the last 12 months, the LiveNova stock price has climbed 38.3%, outperforming the S&P 500's 16.2% return over the same period. With that kind of performance, it's not surprising that an insider may decide to take some gains off the table. Also, although Bianchi sold 1,650 shares, the insider still holds nearly 8,000 shares.

For what's ahead for the stock price, analysts appear generally bullish. Of the 11 who cover the stock, 73% rate it a buy, while 27% rate it a hold, according to CNN. From that group, the median price over the next 12 months is $93. From today's price of $78.18, reaching $93 would represent a gain of nearly 19%. The highest price target from the group is $100, representing a potential gain of almost 28%. The lowest price target, $75, would represent a 4% loss.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.